Skip to main content
EVAX
NASDAQ Life Sciences

Evaxion to Present Novel AI-Based Polio Vaccine Concepts Developed with Gates Foundation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.59
Mkt Cap
$29.358M
52W Low
$1.2
52W High
$12.15
52W Position info
199% above low
Off High info
70% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

EVAX has more than doubled off its 52-week low of $1.2.

Summary

Evaxion announced it will present novel AI-based polio vaccine design concepts, developed in collaboration with the Gates Foundation, and new CMV vaccine data at the World Vaccine Congress.


Key Events · Product Development and Regulatory · EVAX

  • Collaboration with Gates Foundation

    Evaxion developed novel AI-based polio vaccine design concepts in collaboration with the Gates Foundation, showcasing its AI-Immunology™ platform's capabilities.

  • World Vaccine Congress Presentation

    The company will present these novel polio vaccine concepts and new data from its EVX-V1 cytomegalovirus (CMV) vaccine program at the World Vaccine Congress from March 31 to April 2, 2026.

  • AI Platform Validation and Pipeline Expansion

    This collaboration and the expansion into infectious disease vaccine development further validate Evaxion's proprietary AI-Immunology™ platform, demonstrating its versatility beyond cancer vaccines.


Analysis · EVAX · Life Sciences

This filing highlights a significant validation of Evaxion's AI-Immunology™ platform through its collaboration with the Gates Foundation on novel polio vaccine designs. For a company of Evaxion's size, this partnership and expansion into a critical global health area like polio, alongside updates on its CMV vaccine program, represents a substantial positive development. It demonstrates the platform's versatility beyond cancer and could open doors for future funding and partnerships, potentially enhancing the company's long-term value proposition.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVAX was trading at $3.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.4M. The 52-week trading range was $1.20 to $12.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVAX - Latest Insights

EVAX
Nov 19, 2026, 7:05 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $2.32 info
Change: -$0.2241 (-9%) info
Market Cap: $18.765M info
EVAX
Nov 19, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.82
Real-time Price: $2.32 info
Change: -$0.5035 (-18%) info
Market Cap: $18.765M info
EVAX
Oct 23, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.32 info
Change: -$1.72 (-43%) info
Market Cap: $18.765M info
EVAX
Oct 19, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.32 info
Change: -$0.9341 (-29%) info
Market Cap: $18.765M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $2.32 info
Change: -$1.15 (-33%) info
Market Cap: $18.765M info